

Donald J Bastin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7968866/donald-j-bastin-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10 papers	260 citations	5 h-index	11 g-index
11 ext. papers	327 ext. citations	10.2 avg, IF	2.98 L-index

#	Paper	IF	Citations
10	Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. <i>Nature Medicine</i> , 2015 , 21, 530-6	50.5	93
9	Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies. <i>Frontiers in Immunology</i> , 2020 , 11, 1512	8.4	83
8	Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. <i>Journal of Clinical Investigation</i> , 2019 , 129, 5400-5410	15.9	40
7	Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity. <i>Journal of Clinical Investigation</i> , 2019 , 129, 518-530	15.9	25
6	Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. <i>Biomedicines</i> , 2016 , 4,	4.8	8
5	Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. <i>BMJ Open</i> , 2020 , 10, e034714	3	5
4	Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference 2018 , 6, 62		5
3	Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2021 , 39, 448-464	1.3	0
2	A Systematic Review of Evidence Supporting the Use of Autologous Cell Vaccines in the Treatment of Hematological Malignancies. <i>Blood</i> , 2020 , 136, 16-16	2.2	
1	The tale of two organs: allogeneic hematopoietic stem cell transplantation following liver transplantation in a myelofibrosis patient.. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 ,	1.6	